OPPOSED

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff

FILED

DEC 16 2011

JUDGE JESSICA R. MAYER

GARY SKALA,

Plaintiff,

VS.

JOHNSON & JOHNSON COMPANY, JANSSEN PHARMACEUTICA PRODUCTS, L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN PHARMACEUTICA, L.P., a/k/a JANSSEN PHARMACEUTICA, INC., Defendants.

SUPERIOR COURT OF NEW JERSEY LAW DIVISION

MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

TRUI USED ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, any opposition papers, any copy cause having been shown;

:

IT IS on this 11th day of Neur b 2011.

ORDERED that Plaintiff's Motion in Limine that Dr. Hammer Is Only Qualified to Testify as to Psychiatric Matters is hereby granted:

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

Defendants' counsel within seven (7) days of the date of this Order.

The parties having consented to disposition of the motion on the popers and farthe reasons set earth with attacked memorandum.

ĴESSICA R. MAYER, J.S.C.

Skala v. Johnson & Johnson, et al.

Docket No. L-6820-06 (MT)

Memorandum of Decision on Plaintiff's motion in limine to limit the testimony of Defendants' experts, Drs. Hammer and Shelmet:

1. Plaintiff's motion in limine to limit Dr. Hammer's testimony to psychiatric matters.

The court understands that Defendants intend to call Dr. Shelmet, an endocrinologist, as an expert witness at trial. As an endocrinologist with experience in the field of diabetes, and based upon the court's review of Dr. Shelmet's written report and deposition testimony, the court believes that Dr. Shelmet will offer testimony as to the lack of an association between Rispderal® and the development of diabetes. The court also believes that Dr. Shelmet will offer testimony that Plaintiff had multiple risk factors, prior to treatment with Risperdal,® such as family history of diabetes and alcohol consumption, leading to Plaintiff's development of diabetes.

Dr. Hammer is a psychiatrist. As Dr. Hammer admitted during his deposition, he is not a specialist in the field of diabetes and is not an endocrinologist. See Deposition of Dr. Hammer dated August 1, 2011 ("Hammer Dep.") 48:6-12. Further, based upon the expert report of Dr. Hammer for this Plaintiff, dated June 15, 2011, the focus of Dr. Hammer's testimony is addressed to the appropriateness of Risperdal® in the treatment of Mr. Skala. Indeed, based upon his experience and training in the field of addictology, Dr. Hammer stated "it would appear that Alcohol, not Risperdal, should remain the main subject of concern relative to the development of Diabetes." See Dr. Hammer's expert report for Plaintiff Skala dated June 15, 2011 ("Hammer Report") at p. 3. Clearly, based upon this statement, Dr. Hammer leaves it to another expert to offer causation opinions as to why Plaintiff developed diabetes in this case.

Also, the court reviewed the entirety of Dr. Hammer's deposition in this case. During his deposition, Dr. Hammer conceded that he was not asked to determine what caused Plaintiff's diabetes. See Hammer Dep. at 20:8-17. Based upon the court's review of the expert report submitted in Plaintiff's case, Defendants asked Dr. Hammer to examine the role of Risperdal® in the treatment of Plaintiff's mental disorder. If Defendants intend to use the testimony of Dr. Hammer to address the lack of an association between Risperdal® and the development of diabetes, such testimony would be cumulative of the testimony proffered by Dr. Shelmet who possesses medical expertise in the field of diabetes. Therefore, this motion is GRANTED.

林(41~

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

FILED

DEC 16 2011

JUDGE JESSICA R. MAYER

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff

GARY SKALA,

Plaintiff,

VS.

JOHNSON & JOHNSON COMPANY, JANSSEN PHARMACEUTICA PRODUCTS, L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN PHARMACEUTICA, L.P., a/k/a JANSSEN PHARMACEUTICA, INC.,

Defendants.

SUPERIOR COURT OF NEW JERSEY

LAW DIVISION

MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

[PROPOSED] ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, any opposition papers, any reply papers, and the arguments of coursel, and good cause having been shown;

ORDERED that Plaintiff's Motion in Limine that Dr. Hammer Should Be Precluded from Testifying That Risperdal Was Not a Significant Contributing Factor to Plaintiff's Diabetes is hereby granted;

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

Defendants' counsel within seven (7) days of the date of this Order.

| | 220010111111111111111111111111111111111 |
|------------------------------------|---|
| This motion was: Opposed Unopposed | The parties having consented to disposition of the motion on the papers and for the reasons set forth in the attached memorandum. |
| | |

2. Plaintiff's motion in limine to preclude Dr. Hammer from testifying that Risperdal® was not a significant contributing factor to Plaintiff's diabetes.

The court understands that Defendants intend to call Dr. Shelmet, an endocrinologist, as an expert witness at trial. As an endocrinologist with experience in the field of diabetes, and based upon the court's review of Dr. Shelmet's written report and deposition testimony, the court believes that Dr. Shelmet will offer testimony as to the lack of an association between Rispderal® and the development of diabetes. The court also believes that Dr. Shelmet will offer testimony that Rispderal® was not a significant contributing factor to Plaintiff's development of diabetes.

Dr. Hammer is a psychiatrist. As Dr. Hammer admitted during his deposition, he is not a specialist in the field of diabetes and is not an endocrinologist. Further, based upon the expert report dated June 15, 2011 submitted by Dr. Hammer in support of his conclusions regarding Plaintiff Skala, the focus of his testimony involves the appropriateness of Risperdal® in the treatment of Mr. Skala. Indeed, based upon his experience and training in the field of addictology, Dr. Hammer stated "it would appear that Alcohol, not Risperdal, should remain the main subject of concern relative to the development of Diabetes." See Hammer Report at 3.

During his deposition, Dr. Hammer conceded that he was not asked to determine the cause of Plaintiff's diabetes. Based upon the court's review of the expert report submitted in Plaintiff's case, Defendants asked Dr. Hammer to examine the role of Risperdal® in the treatment of Plaintiff's mental disorder. If Defendants intend to use the testimony of Dr. Hammer to opine that Risperdal® was not a significant contributing factor leading to Plaintiff's diabetes, such testimony would be cumulative of the testimony proffered by Dr. Shelmet, who possesses medical expertise in the field of diabetes. Therefore, this motion is **GRANTED**.

5H2

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600 FILED

DEC 1 6 2011 JUDGE JESSICA R. MAYER

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff

SUPERIOR COURT OF NEW JERSEY GARY SKALA. Plaintiff, LAW DIVISION MIDDLESEX COUNTY VS. JOHNSON & JOHNSON COMPANY, CIVIL ACTION JANSSEN PHARMACEUTICA PRODUCTS, L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN CASE CODE 274 PHARMACEUTICA, L.P., a/k/a JANSSEN (Risperdal/Seroquel/Zyprexa Litigation) PHARMACEUTICA, INC., Defendants. DOCKET NO. MID-L-6820-06(MT) [PROPOSED] ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, any opposition papers, any tophy papers, and the arguments of courts, and good cause having been shown;

IT IS on this with day of Deemby, 2011,

ORDERED that Plaintiff's Motion in Limine that Dr. Hammer Should Be Precluded from Testifying That Alcohol Consumption or Any Other Alleged Risk Factor Was a Significant Contributing Factor to Plaintiff's Diabetes is hereby granted in the state of the

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

Defendants' counsel within seven (7) days of the date of this Order.

| OP | PO | SF | ח |
|----|-----|----|---|
| | * * | | |

Unopposed

Opposed

This motion was:

A The parties having consented to disposition of the motion on the papers and for the reasons set forth in the attached memorandum.

3. Plaintiff's motion in limine to preclude Dr. Hammer from testifying that alcohol consumption or any other alleged risk factor was a significant contributing factor to Plaintiff's diabetes.

Based upon his clinical experience and training, Dr. Hammer treats patients who suffer from alcohol dependence and alcohol abuse. Dr. Hammer reviewed Plaintiff's medical records and opined that Plaintiff suffered from alcohol dependence/abuse. During his deposition, Dr. Hammer testified that, in addition to his expertise and experience in the field of psychiatry, he is an "addictionologist in the field of addiction psychiatry." Hammer Dep. at 35:25-36:2. Therefore, Dr. Hammer is qualified to offer testimony about the impact alcohol can have on the treatment of mental disorders. In reviewing the deposition testimony of Dr. Hammer, it was Plaintiff's counsel who questioned the doctor regarding alcohol consumption and the role that alcohol may have played in contributing to Plaintiff's diabetes.

Based upon the court's review of Dr. Shelmet's written report and deposition testimony, the court believes that Dr. Shelmet will offer testimony that Plaintiff had multiple risk factors that may have contributed to Plaintiff's development of diabetes, including Plaintiff's excess consumption of alcohol.

Based on the foregoing, this motion is **GRANTED IN PART**. Dr. Hammer's experience and training in addictology qualifies him to offer testimony as to Plaintiff's alcohol addiction and alcohol dependence and the impact alcohol may have had on Plaintiff's mental condition. However, as Dr. Hammer repeated throughout his deposition testimony, he is not an expert in the field of diabetes and is not an endocrinologist trained in assessing the causes of diabetes in a particular patient.

KOHY

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

FILED

DEC 16 2011

JUDGE JESSICA R. MAYER

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff

GARY SKALA,

Plaintiff,

VS.

JOHNSON & JOHNSON COMPANY,
JANSSEN PHARMACEUTICA PRODUCTS,
L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN
PHARMACEUTICA, L.P., a/k/a JANSSEN
PHARMACEUTICA, INC.,
Defendants.

SUPERIOR COURT OF NEW JERSEY LAW DIVISION

MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

PROPOSED ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having been considered the moving papers, engrepposition papers, engreppy papers, and the arguments of councel, and good cause having been shown;

IT IS on this lit day of Deenh, 2011,

ORDERED that Plaintiff's Motion in Limine that Dr. Hammer Should Be Precluded from Testifying That Major Psychiatric Disorders Are Direct Causes of Diabetes is hereby dead;

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

OPPOSED

JESSICA R. MAYER, J.S.C.

This motion was:

Opposed

Unopposed

Unopposed

JESSICA R. MAYER, J.S.C.

*The parties having consented to the disposition of the motion on the papers and for the reasons set forth in the attached memorandum.

Defendants' counsel within seven (7) days of the date of this Order.

4. Plaintiff's motion in limine to preclude Dr. Hammer's testimony that major psychiatric disorders are direct causes of diabetes.

Dr. Hammer was not asked to determine what caused Plaintiff to develop diabetes. However, as a practicing psychiatrist with significant training and experience, Dr. Hammer has treated many patients with major psychiatric disorders. To the extent that Dr. Hammer has treated patients with major psychiatric disorders who also suffer from diabetes, the court will allow such testimony based upon Dr. Hammer's experience but will consider an appropriate limiting instruction to be given to the jury. Therefore, this motion is **DENIED**.

*0747

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

FILED

DEC 16 2011

JUDGE JESSICA R. MAYER

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff

GARY SKALA,

Plaintiff.

VS.

JOHNSON & JOHNSON COMPANY, JANSSEN PHARMACEUTICA PRODUCTS, L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN PHARMACEUTICA, L.P., a/k/a JANSSEN PHARMACEUTICA, INC.,

Defendants.

SUPERIOR COURT OF NEW JERSEY

LAW DIVISION

MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

[PROPOSED] ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having been considered the moving papers, any opposition papers, any capty papers, and the arguments of counterly and good cause having been shown;

:

:

IT IS on this with day of been w, 2011,

ORDERED that Plaintiff's Motion in Limine that Dr. Hammer Should Be Precluded from Testifying That Weight Gain Was a Risk Factor for Plaintiff's Diabetes is hereby granted;

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

The partie having consented to disposition My the motion on the papers and for the

OPPOSED

5. Plaintiff's motion in limine to preclude Dr. Hammer's testimony that weight gain was a risk factor for Plaintiff's diabetes.

Dr. Hammer was not asked to determine what caused Plaintiff to develop diabetes. Defendants may proffer the testimony of Dr. Shelmet as to the cause(s) of Plaintiff's diabetes, including weight gain, alcohol, and family history, if supported by the evidence in this case. Therefore, this motion is **GRANTED**.



EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

FILED

DEC 16 2011

JUDGE JESSICA R. MAYER

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff

GARY SKALA. SUPERIOR COURT OF NEW JERSEY Plaintiff. LAW DIVISION MIDDLESEX COUNTY VS. JOHNSON & JOHNSON COMPANY, CIVIL ACTION JANSSEN PHARMACEUTICA PRODUCTS, L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN CASE CODE 274 PHARMACEUTICA, L.P., a/k/a JANSSEN (Risperdal/Seroquel/Zyprexa Litigation) PHARMACEUTICA, INC., Defendants. DOCKET NO. MID-L-6820-06(MT) PROPOSED ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, any opposition papers, any opposition papers, any opposition papers, any opposition papers, and the arguments of coursel, and good cause having been shown;

IT IS on this (the day of Deemby, 2011,

ORDERED that Plaintiff's Motion in Limine that Dr. Hammer Should Be Precluded

From Opinion that Risperdal May Have Prevented a Tragedy in the Skala Household is hereby

granted for factorial for the state of the

IT IS FURTHER ORDERED that a copy of this Order shall be served-upon

Defendants' counsel within seven (7) days of the date of this Order.

| OPP | OS | El |) |
|-----|----|----|---|
|-----|----|----|---|

ESSICA R. MAYER, J.S.C.

| This motion was: |
|------------------|
| Opposed |
| Unopposed |

A The parties having consented to disposition of the motion on the papers and for the reasons set forth in the attacked memorandum.

6. Plaintiff's motion in limine to preclude Dr. Hammer's testimony that Risperdal® may have prevented a tragedy in Plaintiff's household.

Having reviewed all of the medical evidence regarding Plaintiff's condition, Dr. Hammer opined in his written expert report dated June 15, 2011 that prescribing Risperdal® to Plaintiff was appropriate and that Plaintiff benefitted from Risperdal®. As a board certified psychiatrist, Dr. Hammer is permitted to offer his expert opinion regarding the benefits of Risperdal® based upon Plaintiff's specific mental condition. However, as Dr. Hammer was never Plaintiff's treating doctor, the court shall not permit Dr. Hammer to speculate that Plaintiff's ingestion of Risperdal® may have prevented a household tragedy. Therefore, this motion is GRANTED IN PART.

* b758

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

FILED

DEC 16 2011 JUDGE JESSICA R. MAYER

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff

GARY SKALA,

Plaintiff,

VS.

JOHNSON & JOHNSON COMPANY, JANSSEN PHARMACEUTICA PRODUCTS, L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN PHARMACEUTICA, L.P., a/k/a JANSSEN PHARMACEUTICA, INC.,

Defendants.

SUPERIOR COURT OF NEW JERSEY

LAW DIVISION

MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

[PROPOSED] ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, and opposition papers, are reply papers, and the arguments of course, and good cause having been shown;

IT IS on this low day of been 2011,

ORDERED that Plaintiff's Motion in Limine that Dr. Shelmet Should Be Precluded from Testifying as to Any Relative Risk Assessment of Risperdal Consumption Versus Other Diabetic Risks is hereby granted;

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

Défendants' counsel within seven (7) days of the date of this Order.

| OPPOSED | JESSICA R. MAYER, J.S.C. |
|--------------------------------------|---|
| This motion was: Opposed Unopposed | *The parties having consented to disposition of the motion on the papers and for the reasons set forth in the attached memorandem |

7. Plaintiff's motion in limine to preclude Dr. Shelmet's testimony as to any relative risk assessment of Risperdal® consumption versus other diabetic risks.

Plaintiff's motion is overly broad and vague. The court must await the trial testimony to determine the foundation upon which Dr. Shelmet bases his belief that he cannot assign a specific degree of relative risk for each risk factor that may have led to Plaintiff's development of diabetes. Therefore, this motion is **DENIED**.



EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff

FILED

DEC 16 2011 JUDGE JESSICA R. MAYER

GARY SKALA.

Plaintiff,

VS.

OPPOSED

JOHNSON & JOHNSON COMPANY,
JANSSEN PHARMACEUTICA PRODUCTS,
L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN
PHARMACEUTICA, L.P., a/k/a JANSSEN
PHARMACEUTICA, INC.,
Defendants.

SUPERIOR COURT OF NEW JERSEY

LAW DIVISION

MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

(PROPOSED) ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, any opposition papers, any coply papers, and the organisates of country and good cause having been shown;

IT IS on this with day of December, 2011,

ORDERED that Plaintiff's Motion in Limine to Exclude any reference to Mr. Skala's wife's history of smoking tobacco from Evidence at Trial is hereby granted;

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

Defendants' counsel within seven (7) days of the date of this Order.

A The parties having consented to disposition of the motion on the papers and for the reasons set forth in the attached

JESSICA R. MAYER, J.S.C.

Skala v. Johnson & Johnson, et al.

Docket No. L-6820-06 (MT)

Memorandum of Decision on Plaintiff's motions in limine to exclude certain case specific subjects from evidence at trial

1. Plaintiff's motion in limine to exclude any reference to Plaintiff's wife's history of smoking tobacco.

Defendants agree not to introduce such evidence at trial unless Plaintiff "opens the door." Neither party shall argue or comment on this issue unless the court determines that the other party has "opened the door." Therefore, this motion is **GRANTED**.

#0753

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff FILED

DEC 16 2011

JUDGE JESSICA R. MAYER

GARY SKALA. SUPERIOR COURT OF NEW JERSEY Plaintiff, LAW DIVISION MIDDLESEX COUNTY VS. JOHNSON & JOHNSON COMPANY, CIVIL ACTION JANSSEN PHARMACEUTICA PRODUCTS. L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN CASE CODE 274 PHARMACEUTICA, L.P., a/k/a JANSSEN (Risperdal/Seroquel/Zyprexa Litigation) PHARMACEUTICA, INC., Defendants. DOCKET NO. MID-L-6820-06(MT) [PROPOSED] ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, any opposition papers, any reply papers, and the arguments of souncel, and good cause having been shown;

IT IS on this 16th day of December, 2011,

ORDERED that Plaintiff's Motion in Limine to Exclude any reference to Mr. Skala's history of bankruptcy from Evidence at Trial is hereby granted;

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

Defendants' counsel within seven (7) days of the date of this Order.

* The parties have consented to disposition
of the motion on the papers and for the
reasons let forth in the attached munoraudium.

JESSICA R. MAYER, J.S.C.

OPPOSED

2. Plaintiff's motion in limine to exclude any reference to Plaintiff's history of bankruptcy.

Defendants agree not to introduce such evidence at trial unless Plaintiff asserts a claim for lost wages. Neither party shall argue or comment on this issue unless the court determines that the other party has "opened the door." Therefore, this motion is **GRANTED**.

* 0754

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff FILED

DEC 16 2011

JUDGE JESSICA R. MAYER

GARY SKALA,

Plaintiff,

VS.

JOHNSON & JOHNSON COMPANY,
JANSSEN PHARMACEUTICA PRODUCTS,
L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN
PHARMACEUTICA, L.P., a/k/a JANSSEN
PHARMACEUTICA, INC.,
Defendants.

SUPERIOR COURT OF NEW JERSEY

LAW DIVISION

:

:

•

MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

TROPOSED ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having head and considered the moving papers, any opposition papers, any opposition papers, and the arguments of coursel, and good cause having been shown;

IT IS on this 14th day of Decruber, 2011,

ORDERED that Plaintiff's Motion in Limine to Exclude any reference to Mr. Skala's disability or social security benefits applications or receipt of benefits from Evidence at Trial is hereby granted;

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

Defendants' counsel within seven (7) days of the date of this Order.

This motion was: * The parties have consented to disposition of the motion on the papers and for the reasons set forth in the attached memorandum. ____Opposed

____ Unopposed

3. Plaintiff's motion in limine to exclude any reference to Plaintiff's disability or social security benefits applications or receipt of benefits.

If Plaintiff seeks to introduce testimony in support of a claim for lost wages as a result of his diabetes, then Defendants may be able to use Plaintiff's applications for disability and/or social security to rebut any claim for wage losses due to diabetes. Further, Plaintiff's applications for disability and/or social security may contain information related to Plaintiff's mental and physical conditions at issue in this case which may or may not be admissible at trial. Thus, the court must await the trial testimony to further rule on this issue. Therefore, this motion is **DENIED**.

Notwithstanding this ruling, Defendants shall not refer to Plaintiff's receipt of disability and/or social security benefits to the extent that such statements are made for the sole purpose of implying to the jury that Plaintiff has been remedied through receipt of such benefits.

\$1075S

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff

FILED

DEC 16 2011 JUDGE JESSICA R. MAYER

SUPERIOR COURT OF NEW JERSEY

GARY SKALA.

Plaintiff,

VS.

JOHNSON & JOHNSON COMPANY, JANSSEN PHARMACEUTICA PRODUCTS, L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN PHARMACEUTICA, L.P., a/k/a JANSSEN PHARMACEUTICA, INC., Defendants. ĺ

LAW DIVISION
MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

PROPOSED ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, any opposition papers, any reply papers, and the arguments of counsel, and good cause having been shown;

IT IS on this link day of De unber, 2011,

ORDERED that Plaintiff's Motion in Limine to Exclude any reference to Mr. Skala's family history of mental illness from Evidence at Trial is hereby granted;

IT IS FURTHER ORDERED that a copy of this Order shall be served upon Defendants' counsel within seven (7) days of the date of this Order.

A The parties have consented to a special disposition of the motion on the papers and for the reasons get forth in the

JESSICA H. MAYER, J.S.C.

OPPOSED

4. Plaintiff's motion in limine to exclude any reference to Plaintiff's family history of mental illness.

The court is unaware of any testimony indicating that Plaintiff's treating doctors relied on a family history of mental illness in prescribing Risperdal® to Plaintiff. Therefore, this motion is **GRANTED**.

The court may revisit this ruling if there is evidence or testimony that a family history of mental illness was considered by Plaintiff's physician in prescribing Risperdal® to Plaintiff.

XXXX

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff FILED

DEC 1 6 2011 JUDGE JESSICA R. MAYER

GARY SKALA,

Plaintiff,

VS.

JOHNSON & JOHNSON COMPANY, JANSSEN PHARMACEUTICA PRODUCTS, L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN PHARMACEUTICA, L.P., a/k/a JANSSEN PHARMACEUTICA, INC., Defendants. SUPERIOR COURT OF NEW JERSEY

LAW DIVISION

MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

[PROPOSED] ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, and opposition papers, and opposition papers, and the arguments of coursel, and good cause having been shown;

:

IT IS on this _ (th day of _)e and _, 2011,

ORDERED that Plaintiff's Motion in Limine to Exclude any reference to whether or not Mr. Skala spoke to his doctor about the metabolic risks of Risperdal after seeing a lawyer's advertisement from Evidence at Trial is hereby granted in Park

IT IS FURTHER ORDERED that a copy of this Order shall be served upon

OPPOSED

OPPOSED

OPPOSED

OPPOSED

OPPOSED

This motion was:

____Opposed

____Opposed

____Unopposed

The parties have consented to disposition
of the motion on the papers and for
the reasons set forth in the attacked
memorandum.

5. Plaintiff's motion in limine to exclude any reference to whether or not Plaintiff spoke to his doctor about the metabolic risks of Risperdal® after seeing a lawyer's advertisement.

The timing of discussions (before/after seeing a legal advertisement) that Plaintff may have had with his doctor about the metabolic risks of Risperdal® is irrelevant. However, discussions between Plaintiff and his prescribing physician at the time the drug was prescribed are relevant to the "learned intermediary" doctrine and whether Plaintiff's prescribing physician was aware of an alleged association between the use of Risperdal® and the development of diabetes. Therefore, this motion is **GRANTED IN PART**.

OPPOSED

EPSTEIN ARLEN, LLC

A New Jersey Limited Liability Corporation 220 Davidson Avenue, Suite 102 Somerset, New Jersey 08873 Tel. (732) 828-8600

BAILEY PERRIN BAILEY

440 Louisiana Street, Suite 2100 Houston, Texas 77002 (713) 425-7100 Telephone Attorneys for Plaintiff FILED

DEC 1 6 2011

JUDGE JESSICA R. MAYER

GARY SKALA.

Plaintiff,

VS.

JOHNSON & JOHNSON COMPANY, JANSSEN PHARMACEUTICA PRODUCTS, L.P. a/k/a JANSSEN, L.P., a/k/a JANSSEN PHARMACEUTICA, L.P., a/k/a JANSSEN PHARMACEUTICA, INC.,

Defendants.

SUPERIOR COURT OF NEW JERSEY

LAW DIVISION

MIDDLESEX COUNTY

CIVIL ACTION

CASE CODE 274

(Risperdal/Seroquel/Zyprexa Litigation)

DOCKET NO. MID-L-6820-06(MT)

PROPOSED ORDER

THIS MATTER having been brought before the Court by Bailey Perrin Bailey and Epstein Arlen, attorneys for Plaintiff Gary Skala; the Court having heard and considered the moving papers, any opposition papers, any rophy papers, and the arguments of counsel, and good cause having been shown;

:

IT IS on this 11th day of December, 2011,

ORDERED that Plaintiff's Motion in Limine to Exclude any reference to Mr. Skala's denich, alleged family history of diabetes from Evidence at Trial is hereby granted;

IT IS FURTHER ORDERED that a copy of this Order shall be served upon Defendants' counsel within seven (7) days of the date of this Order.

the motion on the popers and for the reasons set parth in the attached memorandum ESSICA R. MAYER, J.S.C.

6. Plaintiff's motion in limine to exclude any reference to Plaintiff's alleged family history of diabetes.

Family history of diabetes is a risk factor for the development of diabetes and is relevant to the issues in this case. There is conflicting testimony between what Plaintiff's wife told Plaintiff's treating physician about Plaintiff's family history and Plaintiff's recollection of his family history. Further, Plaintiff's case specific expert relied on Plaintiff's recollection of a family history of diabetes in rendering his expert opinions in this case. The conflicting testimony as to Plaintiff's family history of diabetes is relevant and may be presented to the jury so that the jury may evaluate and assess the credibility of the party offering the testimony. Therefore, this motion is **DENIED**.